By Nana O 
Monitoring minuscule fragments of DNA shed by dying tumor cells in the bloodstream offers a powerful new method for predicting the recurrence of stage III melanoma, according to a landmark study led by researchers at NYU Langone Health and its Perlmutter Cancer Center. This pioneering research, published in the esteemed journal The Lancet Oncology, suggests that analyzing circulating tumor DNA (ctDNA) could revolutionize how oncologists identify high-risk patients and tailor treatment strategies for one of the deadliest forms of skin cancer.
The study, the largest of its kind to date focusing on ctDNA as a predictor for recurrence in stage III melanoma, involved nearly 600 men and women who had previously participated in a clinical trial. These participants, hailing from diverse geographical locations including Europe, North America, and Australia, provided blood samples that were meticulously analyzed for ctDNA. The findings indicate that the presence of ctDNA before treatment commencement is a strong harbinger of future disease progression. Specifically, approximately 80% of stage III melanoma patients with detectable ctDNA levels prior to initiating therapy to suppress their tumors went on to experience a recurrence.
Early Detection: A Crucial Advance in Melanoma Management
Stage III melanoma represents a critical juncture in the disease’s progression, characterized by the spread of tumor cells from the primary skin site to nearby lymph nodes. Following surgical removal of these affected lymph nodes, a procedure that aims to eliminate microscopic disease, detecting residual cancer or early signs of recurrence can be exceptionally challenging. Conventional imaging techniques, such as X-rays and CT scans, often lack the sensitivity to pinpoint these nascent threats, leaving a critical window for the cancer to re-establish itself undetected. This diagnostic gap has long spurred the search for more sensitive and proactive methods to monitor disease activity.
The NYU Langone Health study directly addresses this unmet clinical need by demonstrating the remarkable predictive power of ctDNA. The research team found that not only did patients with detectable ctDNA experience recurrence more frequently, but their disease also returned significantly faster. On average, these patients saw their cancer return more than four times faster compared to those with no detectable ctDNA. Furthermore, the study established a dose-response relationship: the higher the levels of ctDNA detected, the more rapid the subsequent cancer recurrence. This granular insight into disease kinetics underscores the potential of ctDNA as a dynamic biomarker.
"Our findings suggest that circulating tumor DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy," stated Mahrukh Syeda, MS, the study’s lead author and a research scientist in the Ronald O. Perlman Department of Dermatology at NYU Grossman School of Medicine. "In the future, such assessments may be used routinely in the clinic to help guide treatment decisions."
The Science Behind Circulating Tumor DNA
The ctDNA method hinges on the principle that as tumor cells die, they release fragments of their genetic material into the bloodstream. These fragments, known as circulating tumor DNA, carry the specific mutations characteristic of the cancer. By focusing on the most prevalent mutations found in melanoma cells, researchers can isolate and quantify these DNA fragments. This technique offers a non-invasive window into the body’s tumor burden, providing real-time information about the disease’s presence and activity.
The study’s implications extend beyond initial detection. The research team also observed that nearly all patients who had detectable ctDNA levels at various time points during treatment – specifically at three, six, nine, or 12 months – ultimately experienced melanoma recurrence. This finding is particularly significant, as it suggests that the appearance of ctDNA, even in patients who initially tested negative before therapy, could serve as an early warning sign of disease worsening or progression.
Building on Previous Successes: A Growing Body of Evidence
This latest investigation builds upon a growing body of evidence supporting the utility of ctDNA in oncology. Previous research has already established the accuracy of ctDNA tests in tracking the progression of other complex cancers, including colorectal and breast cancer. In a related study conducted in 2021, the same research team found that higher ctDNA levels in patients with stage IV melanoma – cancer that has metastasized throughout the body – were associated with a poorer prognosis and reduced chances of survival. Moreover, that earlier work demonstrated that changes in ctDNA measurements during treatment could effectively stratify patients into those with better or worse survival outcomes.
The current study represents a significant expansion of this research, specifically targeting the complexities of stage III melanoma. By comparing ctDNA measurements with clinical evidence of cancer recurrence, the researchers employed robust statistical analyses to account for various factors that could influence recurrence rates, such as a patient’s sex, age, and the specific type of therapy received. This comprehensive approach strengthens the validity of their findings and highlights the independent predictive power of ctDNA.
A Superior Predictor? Comparing ctDNA to Existing Methods
One of the most compelling findings of the study is the comparative performance of ctDNA assessment against other experimental tests. The results indicated that assessing ctDNA levels was as effective, and in some cases even superior, at predicting recurrence than other experimental tests that examine the tumor itself. These comparison tests included those that measure immune activity within a group of cancer cells, suggesting that ctDNA provides a more direct and potentially more accurate measure of the disease’s presence and behavior.
David Polsky, MD, PhD, the study’s senior author and a distinguished dermatologist and professor at NYU Langone Health, emphasized the direct nature of ctDNA analysis. "Unlike standard, tissue-based analyses of tumor cells, which can only suggest the likelihood of recurrence, circulating tumor DNA tests provide a clear, direct measure of the disease itself and can tell us outright that melanoma has returned," Dr. Polsky stated. This distinction is crucial in clinical decision-making, where definitive information can lead to more timely and appropriate interventions.
Future Directions and Clinical Integration
While the study presents a highly promising outlook for ctDNA as a predictive tool, researchers acknowledge that challenges remain. Dr. Polsky cautioned that in a minority of cases, cancer still recurred even when patients initially received a negative ctDNA test before commencing therapy. This observation highlights the ongoing need to refine the sensitivity of ctDNA tests.
In response, the research team plans to focus on improving the test’s sensitivity to capture even lower levels of ctDNA, thereby potentially increasing its accuracy. Furthermore, a critical next step involves rigorously evaluating whether using ctDNA-guided treatment decisions in a clinical setting can demonstrably improve patient outcomes, including survival rates and overall quality of life. This translational research aims to bridge the gap between scientific discovery and tangible patient benefit.
A Collaborative Effort with Broad Implications
The extensive scope of this research is a testament to a significant collaborative effort. Funding support for the study was provided by Novartis Pharmaceuticals Corporation. The research team comprised numerous investigators from NYU Langone Health, including Jennifer Wiggins-Crosby, PhD, and Saim Ali, BA. International collaborators also played a pivotal role, with contributions from experts such as Georgina Long, MD, PhD, at the University of Sydney, Australia; James Garrett, PhD, at Novartis Pharmaceuticals Corporation in Cambridge, Massachusetts; Victoria Atkinson, MD, at the University of Queensland, Australia; Mario Santinami, MD, at the National Cancer Institute of Milan, Italy; Dirk Schadendorf, MD, at the University of Duisburg-Essen, Germany; Axel Hauschild, MD, at the University Hospital, Campus Kiel, Germany; Michael Millward, MD, at the University of Western Australia; Mario Mandala, MD, at the University of Perugia, Italy; Vanna Chiarion-Sileni, MD, at the Veneto Institute of Oncology, Italy; Michael Smylie, MD, at the Cross Cancer Institute, Canada; Georgy Manikhas, MD, at St. Petersburg Oncology Hospital, Russia; Reinhard Dummer, MD, at the University Hospital Zurich Skin Cancer Center, Switzerland; Sachin Bajirao Adnaik, PhD, at Novartis Healthcare Pvt. Ltd., India; and Monique Tan, MD, MPH, and Maya Dajee, PhD, at Novartis Pharmaceuticals, USA.
The potential implications of this research are far-reaching. For patients diagnosed with stage III melanoma, the ability to accurately predict recurrence could lead to more personalized treatment plans, potentially sparing them from unnecessary or ineffective therapies and allowing for earlier intervention if the disease does return. For oncologists, ctDNA offers a powerful new biomarker to complement existing diagnostic tools, enhancing their ability to manage this aggressive cancer. As the field of liquid biopsy continues to mature, ctDNA analysis stands poised to become an indispensable component of precision oncology, offering hope for improved outcomes in the fight against melanoma and potentially other cancers. The ongoing commitment to refining these technologies and integrating them into clinical practice holds the promise of saving lives and enhancing the quality of life for countless patients.
